Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors

Inclusion Criteria:

* Clinical and pathological confirmation of peritoneal carcinomatosis from gastric, colorectal and ovarian cancers or primary peritoneal tumors.
* Patients aged between 18 and 78 years.
* Performance status sec. ECOG ≤ 2
* Disease progression/relapse after at least one line of previous i.v. standard chemotherapy in gastric cancer and primary peritoneal tumors and two lines in colorectal and ovarian cancers.
* Patients with peritoneal carcinomatosis from ovarian, gastric and colorectal cancers and primary peritoneal cancers not eligible to cytoreductive surgery +/- HIPEC.
* Blood and electrolyte counts, liver, renal and cardiopulmonary function parameters within 10% of the normal range.
* Written informed consent.
* Tumor mass present on CT-scan in order to allow tumor response assessment with RECIST-criteria.

Exclusion Criteria:

* Extra-abdominal metastatic disease, with the exception of isolated pleural carcinomatosis.
* Bowel obstruction.
* Severe renal impairment, myelosuppression, severe hepatic impairment, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias.
* Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system.
* Creatinine clearance \< 60 ml /min.
* Pregnancy.
* Previous treatment reaching the maximum cumulative dose of doxorubicin, daunorubicin, epirubicin, idarubicin and/or other anthracyclines and anthracenediones.
* Known allergy to cisplatin or other platinum-containing compounds or to doxorubicin.
* Patients of both sexes who do not conduct complete abstinence from heterosexual relationships or agree to use an effective clinically acceptable method (with failure rate \<1%) during the study and the following 6 months after the last treatment.